Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07429903 · ClinicalTrials.gov registry record · NA
Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID
A NA study of Long COVID and Cognition, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT07429903 is a NA study of Long COVID and Cognition that has completed, run by University of California, Los Angeles. The registered enrollment target is 31 participants, below the 2,188-participant average among 50 other Long COVID trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07429903, a NA study of Long COVID and Cognition, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Approximately 30% of patients experience "Long-COVID" syndrome presenting with symptoms such as cognitive difficulties ('brain fog'), fatigue, dyspnea, autonomic dysfunction, depression and anxiety, lasting beyond 12 weeks causing significant disability, and threaten health and wellbeing of millions around the world. At the current time, there is no effective treatment for long-COVID. Walnuts contain a mixture of nutrients and phytochemicals include monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), and alpha-linolenic acid (ALA). Walnut consumption was directly associated with cognitive function. The investigators have shown pomegranate that share the same phytonutrient ellagitannins as walnut and mixed nuts including walnuts could increase blood microbiome metabolites of tryptophan metabolite indole propionate and serotonin levels via change of gut microbiota and therefore play an essential role in gut-brain axis including cognitive function. The proposed pilot study will include 76 adults (ages \>40 years) with diagnosis of SARS-CoV2 infection presenting with long-COVID symptoms lasting longer than 12 weeks. They will be randomized 1:1 to usual care vs. an intervention group that will include 2 oz (57g) of walnuts daily into their habitual diet for 12 weeks. The investigators will compare the improvement in symptoms of cognitive complains of "brain fog", fatigue and depression of the active intervention group vs. usual care. The outcome of the investigation of the benefit of walnut consumption will provide important novel information on using dietary sources of polyunsaturated fatty acids and phytochemicals to mitigate the common symptoms of long-COVID. This application was submitted in response to the California Walnut Commission's commodity board topic.
Conditions Studied
Interventions
- OTHER whole food - walnuts
Study Locations (1)
California
- UCLA Center for Human Nutrition - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2025-01-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07429903
The ClinicalTrials.gov registry entry for NCT07429903 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,188-participant average among 50 other Long COVID trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which whole food - walnuts is the first listed.
NCT07429903 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07429903 about?
NCT07429903 is a clinical study titled "Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID". Approximately 30% of patients experience "Long-COVID" syndrome presenting with symptoms such as cognitive difficulties ('brain fog'), fatigue, dyspnea, autonomic dysfunction, depression and anxiety, lasting beyond 12 weeks causing significant disability, and threaten health and wellbeing of millions...
What is the current status of trial NCT07429903?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2023-09-21. Estimated completion is 2025-01-24.
What conditions does trial NCT07429903 study?
This clinical trial studies the following conditions: Long COVID, Cognition, Memory, Brain Fog.
What interventions are being tested in trial NCT07429903?
The interventions under investigation include: whole food - walnuts (OTHER).
Who is sponsoring clinical trial NCT07429903?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07429903 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Sauna for Long Covid
RECRUITING · NA
-
Long COVID Brain Fog: Cognitive Rehabilitation Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.